Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company?) is pleased to announce that it has engaged Guy Ricciardulli for services related to claims for damages...
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company?) announces the multicenter publication of independent research which reports an association between...
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) (?Nanobac? or ?the Company?) announces that scientists at the Baylor College of Medicine, working under a collaborative agreement...
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP)?("Nanobac" or "the Company") announces that its proprietary CE marked Nano-Capture ELISA assay and Nano-Sero IgG ELISA assay currently...
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announces that it has completed Phase I of its 2006 scientific plan advancing Nanobac?s claim that...
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announces the publication of correspondence in the June 23, 2007 issue of The Lancet that demonstrates new...
Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company?) announces that scientists at Mayo Clinic, working under a collaborative agreement with Nanobac have...
Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) announces scientists at Mayo, working under a collaborative agreement with Nanobac Pharmaceuticals Inc., have published an article in...
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announces new evidence that may help solve one of the great puzzles of 21st century medicine was published...
First graph of release, link to view video should read: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5265147 The corrected release reads: STOCKHOLDER CONFERENCE CALL...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 400 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 31275 | 1.0E-6 | CS |
| 26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 17875 | 1.0E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 10260 | 1.0E-6 | CS |
| 156 | -9.0E-6 | -90 | 1.0E-5 | 0.0001 | 1.0E-6 | 90524 | 2.11E-6 | CS |
| 260 | -0.000299 | -99.6666666667 | 0.0003 | 0.0076 | 1.0E-6 | 323175 | 0.0010445 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
